Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single-dose subcutaneous ALX-0141 in healthy postmenopausal women
NL-OMON32748Phase 1Active, not recruiting
- Sponsor
- Ablynx
- Start
- Dec 2009
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, double-blind trial of ALX-0141 in osteoporosis (12 cohorts), sponsored by Ablynx. Primary endpoints: Serum bone turnover biomarkers, Urine biomarkers and 11 more. Started Dec 2009; status: active, not recruiting.
02
Drugs
ALX-0141
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NL-OMON32748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32748.